Clinical trial / 2006
Standard nicotinamide supplementation failed to prevent or delay type 1 diabetes onset in first-degree relatives of affected individuals.
A randomized double-blind placebo-controlled trial evaluated oral standard nicotinamide (1.2 g/m2) versus placebo for 5 years in 40 first-degree relatives of patients with type 1 diabetes. Frequencies of type 1 diabetes development were similar between the intervention and placebo groups. End-of-study ICA frequencies, first-phase insulin release, and insulin sensitivity also showed no differences between groups, with no adverse events reported.
- Study type
- Randomized double-blind placebo-controlled intervention trial
- Who was studied
- 40 first degree relatives of type 1 diabetic patients with persistent ICA (>= 10 JDF units)
- What was measured
- Type 1 diabetes development, ICA frequencies, insulin secretion, and peripheral sensitivity
THE PAPER
Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes.
Cabrera-Rode E, Molina G, Arranz C, Vera M, González P, Suárez R, Prieto M, Padrón S, León R, Tillan J, García I, Tiberti C, Rodríguez OM, Gutiérrez A, Fernández T, Govea A, Hernández J, Chiong D, Domínguez E, Di Mario U, Díaz-Díaz O, Díaz-Horta O. Autoimmunity, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.